Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0443
Trial ID NCT03570892
Disease Non-Hodgkin's Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment Tisagenlecleucel|Kymriah
Generation2nd
PhasePhase3
Recruitment statusActive, Not Recruiting
TitleTisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Year2018
CountryUnited States
Company sponsorNovartis Pharmaceuticals
Other ID(s)CCTL019H2301|2016-002966-29

Clinical Result

Cohort1: tisagenlecleucel
Administration route intravenous infusion
Dosage 0.6~6E8 cells
Donor type Autologous
Pts 162
Age Adult, Older_Adult
Lymph depletion Yes
Outcome median event-free survival:3 months
Adverse reactions 84.0%(Grade 3 or higher adverse events); 1.9%(≥Grade 3 neurologic events)
Cohort2: standard-of-care
Administration route None
Donor type Autologous
Pts 160
Age Adult, Older_Adult
Outcome median event-free survival:3 months
Adverse reactions 90.0%(Grade 3 or higher adverse events)

Relationship Graph

Overview of Knowledge Graph